

TECHNOLOGIES EVALUATED FROM 2012 UNTIL 2017	AMOUNT OF TECHNOLOGIES	DECISION	REASSESSED TECHONOLOGIES
Abatacept	1	Extension of use - change in treatment line	YES
Subcutaneous abatacept	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Subcutaneous abatacept	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Lanreotide	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ursodeoxycholic acid	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Adalimumab, certolizumab, etanercept, infliximab, golimumab, rituximab, abatacept and tocilizumab	8	Exclusion of indication	YES
Adefovir	1	Exclusion from SUS (Delisting)	YES
Adjuvant chemotherapy	1	Exclusion from SUS (Delisting)	YES
Alentuzumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Interferon alfa	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Coagulation Factor IX	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Peginterferon alfa-2a and alfa-2b	2	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Alfataliglicerase	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Enteral or oral nutrition (Impact®)	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ambrisentan	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ambrisentan and Bosentan	2	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
antiretrovirals	2	Exclusion from SUS (Delisting)	YES
Apixaban	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Artemether	1	Exclusion from SUS (Delisting)	YES
Ornithine Aspartate	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Polymyxin B sulfate 10,000 IU, neomycin sulfate 3.5 mg/mL, fluocinolone acetonide 0.25 mg/mL and lidocaine hydrochloride 20 mg/mL	4	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Diagnostic evaluation, laboratory procedures and genetic counseling	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Azathioprine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Azithromycin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
4-pronged walking stick	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Benzathine penicillin	1	Maintenance for the same indication	YES
Bevacizumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Biotin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Boceprevir and telaprevir	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Tiotropium bromide	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Budesonide 200mcg/formoterol 6 mcg	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Budesonide, beclomethasone, fenoterol, salbutamol, formoterol and salmeterol	6	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Wheelchair	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Canakinumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Pen for insulin injection	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Balloon catheter	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Balloon catheter	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ceftriaxone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ceftriaxone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Certolizumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Certolizumab pegol	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Cetuximab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Cetuximab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Cetuximab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Cetuximab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ciclosporin	1	Exclusion of indication	YES
Ciclosporin	1	Exclusion of indication	YES
CID K51.4	1	Exclusion of the International Classification of Diseases (ICD) from the protocol	NO
Cinacalcet	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Hydrocortisone cypionate	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Bariatric surgery	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Clobetasol	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Cinacalcet and paricalcitol	2	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Clozapine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Clozapine, Lamotrigine, Olanzapine, Quetiapine and Risperidone	5	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
CoaguChek	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Corneal Crosslinking	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Dabigatran	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Daivobet	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Darunavir	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Dexrazoxane	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Brazilian Guideline for the Percutaneous Treatment of Abdominal Aortic Aneurysm	1	Protocols/Guidelines approval	NO
Methodological Guideline for Evaluation of Health Technology Performance: Divestment and Reinvestment	1	Protocols/Guidelines approval	NO
Methodological Guideline Methodology for the elaboration of Clinical Guidelines	1	Protocols/Guidelines approval	NO
Guidelines for Care of the Pregnant Woman: Caesarean section	1	Protocols/Guidelines approval	NO
Diagnostic and Therapeutic Guidelines for Prostate Adenocarcinoma	1	Protocols/Guidelines approval	NO
National Guidelines for Assistance to Normal Birth	1	Protocols/Guidelines approval	NO
National Guidelines for the Early Detection of Breast Cancer	1	Protocols/Guidelines approval	NO
Dolutegravir	1	Extension of use - change in treatment line	YES
Dolutegravir and darunavir	2	Extension of use - change in treatment line	YES

Dosage of CA125 antigen	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Doxycycline	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Doxycycline	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Doxycycline	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Doxycycline, streptomycin and rifampicin	3	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Doxycycline Injection and Chloramphenicol Suspension	2	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Elastography	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Entecavir	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Erythropoietin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Erlotinib	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Urinary Sphincter	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Etravirine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Everolimus	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Everolimus	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Everolimus	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Everolimus	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Everolimus, sirolimus and tacrolimus	3	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Examination for typing of the HLA-B allele	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Diagnostic exams for chronic obstructive pulmonary disease (COPD)	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Cervix Type 2 Excision	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Recombinant factor VIII	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Filgrastim and epoetin alfa	2	Exclusion of indication	YES
Fingolimod	1	Extension of use - change in treatment line	YES
Fingolimod	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Fingolimod	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Fingolimod	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Fluticasone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Fluticasone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Fluticasone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Fosamprenavir and didanosine	2	Exclusion from SUS (Delisting)	YES
Dimethyl Fumarate	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Dimethyl Fumarate	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Gefitinib	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Golimumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Golimumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Golimumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Golimumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Golimumab, certolizumab pegol, rituximab, abatacept, tocilizumab, infliximab, adalimumab and etanercept	8	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Heparine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Hepatitis A vaccine	1	Extension of use - widening in the age range	YES
Hydroxyurea	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Hydroxocobalamin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Hylan	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Previous hormone therapy	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Previous hormone therapy	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Icatibant	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Endobronchial valve implantation	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Implantation by catheter of aortic valve bioprosthesis	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Etonogestrel releasing subdermal implant	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Immunoglobulin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Indacaterol	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Infliximab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Insulin analogues	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Insulin analogues	2	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Insulin analogues	2	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Interferon alfa-2b	1	Exclusion of indication	YES
Interferon beta - intramuscular	1	Restriction of use	YES
Low dose iodine therapy	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Ivabradine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ivabradine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Laronidase	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Leflunomide, chloroquine, hydroxychloroquine, methotrexate and sulfasalazine	5	Exclusion of indication	YES
Levetiracetam	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Levetiracetam	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Levetiracetam	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Guided selective lymphadenectomy	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Mammography	1	Extension of use - widening in the age range	YES
Maraviroc	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Implantable cardiac pacemakers and resynchronizers	1	Protocols/Guidelines approval	NO
Special materials for people with mobility restrictions	5	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Infliximab, etanercept, adalimumab and ustequinumab	4	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Mesalazine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Mesalazine	1	Exclusion of indication	YES
Imatinib	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Imatinib	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Rasagiline and levodopa	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Methotrexate	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Methotrexate	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Molgramostim	1	Exclusion from SUS (Delisting)	YES
Monitoring of intracranial pressure	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Nadroparin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Naproxen	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Naproxen	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Naproxen	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Natalizumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Omalizumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Omalizumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Extracorporeal membrane oxygenation	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Home oxygen therapy	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Pulse oximetry	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Palivizumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Paliperidone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Pancrelipase	1	Exclusion from SUS (Delisting)	YES
Paricalcitol	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

PCDT - Hepatitis C and Coinfections	1	Protocols/Guidelines approval	NO
PCDT – Immunosuppression in Adult Liver Transplantation	1	Protocols/Guidelines approval	NO
PCDT Psoriasis Arthritis	1	Protocols/Guidelines approval	NO
PCDT Anemia in Chronic Kidney Disease - Alfaepoetin	1	Protocols/Guidelines approval	NO
PCDT Anemia in Chronic Renal Disease - Iron Replacement	1	Protocols/Guidelines approval	NO
PCDT Antirreviral prophylaxis after post-exposure to risk for HIV infection	1	Protocols/Guidelines approval	NO
PCDT sexually transmitted infections	1	Protocols/Guidelines approval	NO
PCDT Dermatomyositis and Polymyositis	1	Protocols/Guidelines approval	NO
PCDT dystonias and hemifacial spasm	1	Protocols/Guidelines approval	NO
PCDT Bone Mineral Disorder	1	Protocols/Guidelines approval	NO
PCDT Gaucher disease	1	Protocols/Guidelines approval	NO
PCDT Sickle Cell Disease	1	Protocols/Guidelines approval	NO
PCDT Systemic Sclerosis	1	Protocols/Guidelines approval	NO
PCDT Spasticity	1	Protocols/Guidelines approval	NO
PCDT Cystic Fibrosis: Pancreatic Insufficiency	1	Protocols/Guidelines approval	NO

PCDT Cystic Fibrosis: Pulmonary Manifestations	1	Protocols/Guidelines approval	NO
PCDT Uterine leiomyoma	1	Protocols/Guidelines approval	NO
PCDT Rare diseases	1	Protocols/Guidelines approval	NO
PCDT for Chronic viral hepatitis C	1	Protocols/Guidelines approval	NO
PCDT for Managing HIV Infection in Children and Adolescents	1	Protocols/Guidelines approval	NO
PCDT for Vertical Transmission Prevention	1	Protocols/Guidelines approval	NO
PCDT Pre-exposure prophylaxis	1	Protocols/Guidelines approval	NO
PCDT Central Precocious Puberty	1	Protocols/Guidelines approval	NO
PCDT Ankylosing spondylitis	1	Protocols/Guidelines approval	NO
PCDT of rheumatoid arthritis	1	Protocols/Guidelines approval	NO
PCDT for hepatitis B and coinfections	1	Protocols/Guidelines approval	NO
Pegvisomant	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Pegvisomant	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Penicillin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Pentoxifylline	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
PET-CT	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
PET-CT	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
PET-CT	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Procedure wheelchairs	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Procedure for postural adjustment in wheelchairs	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Motorized wheelchair procedure	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Nucleic acid test (NAT)	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Sanitary Surveillance Procedures	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Procedures related to hospital care for hearing health	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Procedures related to the transsexualizer process	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Usage Protocol - Radiation for Corneal Cross-Linking in the Treatment of Keratoconus	1	Protocols/Guidelines approval	NO
Usage Protocol - Zidovudine	1	Protocols/Guidelines approval	NO
Chemoprophylaxis of contacts of leprosy patients	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Radiotherapy of modulated intensity	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Intraoperative Radiotherapy	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Raltegravir	1	Extension of use - widening in the age range	YES
Raltegravir	1	Extension of use - change in treatment line	YES
Strontium ranelate	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ranibizumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ranibizumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Risperidone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Risperidone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Risperidone	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ritonavir	1	Exclusion from SUS (Delisting)	YES

Rituximab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Rituximab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Rituximab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Rivastigmine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Rivastigmine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Rivoraxaban	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Roflumilast	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Sapropterin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Sildenafil	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Sirolimus	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Sistema AngelMed	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Personal modulation system - FM	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Levonorgestrel-releasing intrauterine system	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Levonorgestrel-releasing intrauterine system	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Sofosbuvir and daclatasvir	2	Extension of use - Increase in the period of treatment	YES
Sofosbuvir, daclatasvir and simeprevir	3	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Somatropin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Souvenaid	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Coronary pharmacological stent	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Powdered food supplement	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Tacrolimus	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Tacrolimus	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Tadalafil	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Thalidomide	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Taliglucerase alfa	1	Extension of use - widening in the age range	YES

Remote Monitoring Technology	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Telaprevir and boceprevir	2	Exclusion from SUS (Delisting)	YES
Temozolamide	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Tenofovir	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Tenofovir ans Entricitabine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Subatmospheric Pressure Therapy (VAC)	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Teriflunomide	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Amplification test of nucleic acids (NAT)	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Free Light Chain Test	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Adenosine deaminase (ADA) dosage test	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Sweat test	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Qualitative test for the detection of fetal fibronectin for the diagnosis of preterm labor	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Xpert MTB/RIF test	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
RPR, TRUST, EQI and ELISA	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Ticagrelor	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Tobramicine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Tocilizumab	1	Extension of use - change in treatment line	YES
Tocilizumab	1	Extension of use - change in treatment line	YES
Tofacitinib	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Optical Coherence Tomography	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Botulinum Toxin	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Hematopoietic stem cell transplantation	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Trastuzumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Trastuzumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Trastuzumab	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Non-aesthetic sclerosing treatment of lower limb varicose veins	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
TArsenic trioxide	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Vaccine adsorbed diphtheria, tetanus and pertussis (acellular) - dTpa	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
HPV Vaccine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Influenza vaccine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Tetraviral vaccine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Veruprevir, ritonavir, ombitasvir and dasabuvir	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Veruprevir, ritonavir, ombitasvir and dasabuvir	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO

Western Blot and real-time PCR in patients with HTLV-1-associated adult T-cell leukemia/lymphoma	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
Zidovudine	1	New health technologies / new concentration / new pharmaceutical form / new route of administration or new indication	NO
